UK's biggest vaccine manufacturer announces partnership

Wed, June 10th, 2020

It will develop and manufacture a candidate COVID-19 vaccine...

The UK's biggest vaccine manufacturer has announced a significant global partnership between its parent company CSL, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland to develop and manufacture a candidate COVID-19 vaccine.

Seqirus, whose manufacturing site in Liverpool is the biggest in the UK and one of the largest in Europe, has offered its UK-manufactured adjuvant technology in the development and manufacturing of the COVID-19 vaccine.

The adjuvant - called MF59 - is produced at the Seqirus manufacturing facility in Liverpool. Adjuvants are used in vaccines to improve immune response, and to reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly. MF59 is widely used in the manufacture of Seqirus' influenza vaccines.

Meet the Members

Seqirus UK  Limited logo

Seqirus UK Limited

Point 29, Market Street, Maidenhead, MAIDENHEAD, Berkshire, UK, SL6 8AA

  • T: 0151 705 5000
  • F: 0151 705 5569

Want to upload your own news and events? Click here to find out how

Members can submit news items and events relating to their business